Friday, February 4, 2011

Tamoxifen -- measuring true risks

Li's team studied data on nearly 1,100 Seattle-area women aged 40-79 who were treated for ER-positive breast cancer between 1990 and 2005. The group included 367 women who developed breast cancer in their other breast at least six months after their first diagnosis. << ON T

It's from WebMD. Yes, a whopping 1/3 of women in the study got a relatively rare (so we read, but at 33% -- not rare at all to my mind) breast cancer.

One of the things turning over and over in my mind is: the dreaded double prophelactic (sp?) masectomy. The wife of a childhood friend just opted into one; she had an ovarian cancer when she was pregnant, in a horrifying turn of events, about 15 years ago. She has the gene, and every 1st degree and apparently most 2nd degree female relatives of hers have had one or both cancers. The DDM reduces breast cancer risk to 15%. But, um, what happened to my 11% risk after 5 years of tamoxifen? You know, is it really 33%, taking in consideration the cancers t. causes AND those it doesn't prevent?

No comments:

Post a Comment